As of today (2024-12-12), Natera's share price is $165.98. Natera's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $7.08. Hence, Natera's Price to Tangible Book Ratio of today is 23.45.
The historical rank and industry rank for Natera's Price-to-Tangible-Book or its related term are showing as below:
NTRA'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.63 Med: 11.49 Max: 261.01
Current: 23.44
During the past 11 years, Natera's highest Price to Tangible Book Ratio was 261.01. The lowest was 2.63. And the median was 11.49.
NTRA's Price-to-Tangible-Book is ranked worse than 90.91% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.79
vs NTRA: 23.44
A closely related ratio is called PB Ratio. As of today, Natera's share price is $165.98. Natera's Book Value per Sharefor the quarter that ended in Sep. 2024 was $7.08. Hence, Natera's P/B Ratio of today is 23.45.
Natera Price-to-Tangible-Book Historical Data
The historical data trend for Natera's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Natera's Price-to-Tangible-Book
For the Diagnostics & Research subindustry, Natera's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's Price-to-Tangible-Book Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Natera's Price-to-Tangible-Book falls into.
Natera Price-to-Tangible-Book Calculation
Natera's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Natera Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Natera's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 